Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: A cost-effectiveness analysis

Stefano Capri, Walter Ageno, Davide Imberti, Gualtiero Palareti, Franco Piovella, Gianluigi Scannapieco, Marco Moia

Research output: Contribution to journalArticle

Abstract

Enoxaparin is the most frequently used low-molecular weight heparin in the world, given in order to prevent venous thromboembolism (VTE) in patients undergoing major orthopaedic surgery (MOS). Fondaparinux is an effective and safe alternative. The aim of our study was to compare the cost-effectiveness of enoxaparin and fondaparinux in the extended thromboprophylaxis of patients undergoing MOS in Italy. A decision-tree model was developed: probabilities of symptomatic events were derived from the published trials; use of resources in Italy was evaluated by means of a questionnaire administered to a panel of experts. Only the direct costs of VTE (acute treatment of events and of complications) were considered. Cost units were derived from the current cost of drugs, and from the Italian National Healthcare tariffs in 2007. Incremental cost-effectiveness ratios were analysed at three time points: 30 days, 1 year and 5 years. The higher cost of fondaparinux was counterbalanced by reduced rates of early DVT, early PE and prophylaxis-related major bleeding. If compared with enoxaparin, after 30 days of extended prophylaxis, fondaparinux is associated with a savings of € 48.83 per patient; at the end of the first year, the savings increased to € 72.13, and after 5 years, the savings are € 74.36. One-way sensitivity analysis shows that the results are robust to the variation in unit costs for VTE-related care, or in event rates for both treatments. In conclusion, our model shows that, when administered for extended prophylaxis of VTE following MOS, fondaparinux is more effective and cost saving than enoxaparin.

Original languageEnglish
Pages (from-to)33-40
Number of pages8
JournalInternal and Emergency Medicine
Volume5
Issue number1
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Venous Thromboembolism
Enoxaparin
Italy
Cost-Benefit Analysis
Orthopedics
Costs and Cost Analysis
Decision Trees
Drug Costs
Low Molecular Weight Heparin
fondaparinux
Hemorrhage
Delivery of Health Care
Therapeutics

Keywords

  • Cost-efficacy
  • Enoxaparin
  • Orthopaedic surgery
  • Pentasaccharide
  • Prophylaxis
  • Venous thromboembolism

ASJC Scopus subject areas

  • Emergency Medicine
  • Internal Medicine

Cite this

Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy : A cost-effectiveness analysis. / Capri, Stefano; Ageno, Walter; Imberti, Davide; Palareti, Gualtiero; Piovella, Franco; Scannapieco, Gianluigi; Moia, Marco.

In: Internal and Emergency Medicine, Vol. 5, No. 1, 02.2010, p. 33-40.

Research output: Contribution to journalArticle

@article{12054e3750da49349c454df7c0412f1b,
title = "Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: A cost-effectiveness analysis",
abstract = "Enoxaparin is the most frequently used low-molecular weight heparin in the world, given in order to prevent venous thromboembolism (VTE) in patients undergoing major orthopaedic surgery (MOS). Fondaparinux is an effective and safe alternative. The aim of our study was to compare the cost-effectiveness of enoxaparin and fondaparinux in the extended thromboprophylaxis of patients undergoing MOS in Italy. A decision-tree model was developed: probabilities of symptomatic events were derived from the published trials; use of resources in Italy was evaluated by means of a questionnaire administered to a panel of experts. Only the direct costs of VTE (acute treatment of events and of complications) were considered. Cost units were derived from the current cost of drugs, and from the Italian National Healthcare tariffs in 2007. Incremental cost-effectiveness ratios were analysed at three time points: 30 days, 1 year and 5 years. The higher cost of fondaparinux was counterbalanced by reduced rates of early DVT, early PE and prophylaxis-related major bleeding. If compared with enoxaparin, after 30 days of extended prophylaxis, fondaparinux is associated with a savings of € 48.83 per patient; at the end of the first year, the savings increased to € 72.13, and after 5 years, the savings are € 74.36. One-way sensitivity analysis shows that the results are robust to the variation in unit costs for VTE-related care, or in event rates for both treatments. In conclusion, our model shows that, when administered for extended prophylaxis of VTE following MOS, fondaparinux is more effective and cost saving than enoxaparin.",
keywords = "Cost-efficacy, Enoxaparin, Orthopaedic surgery, Pentasaccharide, Prophylaxis, Venous thromboembolism",
author = "Stefano Capri and Walter Ageno and Davide Imberti and Gualtiero Palareti and Franco Piovella and Gianluigi Scannapieco and Marco Moia",
year = "2010",
month = "2",
doi = "10.1007/s11739-009-0324-6",
language = "English",
volume = "5",
pages = "33--40",
journal = "Internal and Emergency Medicine",
issn = "1828-0447",
publisher = "Springer-Verlag Italia s.r.l.",
number = "1",

}

TY - JOUR

T1 - Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy

T2 - A cost-effectiveness analysis

AU - Capri, Stefano

AU - Ageno, Walter

AU - Imberti, Davide

AU - Palareti, Gualtiero

AU - Piovella, Franco

AU - Scannapieco, Gianluigi

AU - Moia, Marco

PY - 2010/2

Y1 - 2010/2

N2 - Enoxaparin is the most frequently used low-molecular weight heparin in the world, given in order to prevent venous thromboembolism (VTE) in patients undergoing major orthopaedic surgery (MOS). Fondaparinux is an effective and safe alternative. The aim of our study was to compare the cost-effectiveness of enoxaparin and fondaparinux in the extended thromboprophylaxis of patients undergoing MOS in Italy. A decision-tree model was developed: probabilities of symptomatic events were derived from the published trials; use of resources in Italy was evaluated by means of a questionnaire administered to a panel of experts. Only the direct costs of VTE (acute treatment of events and of complications) were considered. Cost units were derived from the current cost of drugs, and from the Italian National Healthcare tariffs in 2007. Incremental cost-effectiveness ratios were analysed at three time points: 30 days, 1 year and 5 years. The higher cost of fondaparinux was counterbalanced by reduced rates of early DVT, early PE and prophylaxis-related major bleeding. If compared with enoxaparin, after 30 days of extended prophylaxis, fondaparinux is associated with a savings of € 48.83 per patient; at the end of the first year, the savings increased to € 72.13, and after 5 years, the savings are € 74.36. One-way sensitivity analysis shows that the results are robust to the variation in unit costs for VTE-related care, or in event rates for both treatments. In conclusion, our model shows that, when administered for extended prophylaxis of VTE following MOS, fondaparinux is more effective and cost saving than enoxaparin.

AB - Enoxaparin is the most frequently used low-molecular weight heparin in the world, given in order to prevent venous thromboembolism (VTE) in patients undergoing major orthopaedic surgery (MOS). Fondaparinux is an effective and safe alternative. The aim of our study was to compare the cost-effectiveness of enoxaparin and fondaparinux in the extended thromboprophylaxis of patients undergoing MOS in Italy. A decision-tree model was developed: probabilities of symptomatic events were derived from the published trials; use of resources in Italy was evaluated by means of a questionnaire administered to a panel of experts. Only the direct costs of VTE (acute treatment of events and of complications) were considered. Cost units were derived from the current cost of drugs, and from the Italian National Healthcare tariffs in 2007. Incremental cost-effectiveness ratios were analysed at three time points: 30 days, 1 year and 5 years. The higher cost of fondaparinux was counterbalanced by reduced rates of early DVT, early PE and prophylaxis-related major bleeding. If compared with enoxaparin, after 30 days of extended prophylaxis, fondaparinux is associated with a savings of € 48.83 per patient; at the end of the first year, the savings increased to € 72.13, and after 5 years, the savings are € 74.36. One-way sensitivity analysis shows that the results are robust to the variation in unit costs for VTE-related care, or in event rates for both treatments. In conclusion, our model shows that, when administered for extended prophylaxis of VTE following MOS, fondaparinux is more effective and cost saving than enoxaparin.

KW - Cost-efficacy

KW - Enoxaparin

KW - Orthopaedic surgery

KW - Pentasaccharide

KW - Prophylaxis

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=76049086587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76049086587&partnerID=8YFLogxK

U2 - 10.1007/s11739-009-0324-6

DO - 10.1007/s11739-009-0324-6

M3 - Article

C2 - 19890611

AN - SCOPUS:76049086587

VL - 5

SP - 33

EP - 40

JO - Internal and Emergency Medicine

JF - Internal and Emergency Medicine

SN - 1828-0447

IS - 1

ER -